Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2009-07-17 Interim / Quarterly Rep…
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, a foreign private issuer, submitted to the SEC. It reports financial results for the first half of 2009, including detailed financial data such as net sales, operating income, net income, and earnings per share. The document includes comprehensive operational and financial performance information, business reviews, and outlook commentary. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F or 40-F. The content is a detailed interim financial report covering a period shorter than a full fiscal year (half-year). Therefore, this document fits the definition of an Interim / Quarterly Report (IR). It is not an announcement or a brief summary but contains substantive financial data and analysis.
2009-07-17 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing the approval of a new drug (Rasilez) by the Japanese Ministry of Health. It includes detailed product information, clinical trial references, and forward-looking statements. There are no financial statements, management discussion and analysis, or detailed financial results presented. The document is not an annual or interim report, nor is it a transcript, audit report, or governance-related filing. It is a regulatory filing providing material information to investors but does not fit into more specific categories like earnings release or capital update. Given the nature and format, it best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not neatly fit into other categories. The document length (12,612 characters) is substantial, indicating it is not a mere announcement of a report publication but a full regulatory filing of a press release.
2009-07-09 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing the delivery of the 250 millionth treatment of Coartem and Novartis joining the United Against Malaria partnership. There are no financial statements, detailed financial data, or comprehensive management analysis present. The document is informational and serves as a regulatory announcement of a corporate event and partnership, not a full financial report or earnings release. Given the nature of the content and the form type (6-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2009-07-06 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release about receiving a Complete Response letter from the FDA regarding a vaccine application. It includes detailed information about the vaccine, disease background, and company information, but does not contain financial statements or detailed financial analysis. The document is about regulatory communication and company news rather than a financial report or earnings release. It is not an Annual Report, Interim Report, Earnings Release, or any other financial filing. It is a regulatory announcement/report filed on Form 6-K, which is typically classified under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2009-07-02 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It contains detailed clinical trial data and results related to the drug Afinitor and its use in treating pancreatic neuroendocrine tumors. The document is an investor relations release presenting clinical trial results and drug information, not a full annual or quarterly financial report. It is not an earnings release, audit report, or management report. It is a regulatory filing providing material information to investors about clinical trial progress and drug development status. The document length is substantial (15,000 characters), and it is a formal SEC filing (Form 6-K), which is typically classified under Regulatory Filings (RNS) as it does not fit other specific categories like earnings, annual report, or capital update. Therefore, the appropriate classification is Regulatory Filings (RNS).
2009-06-30 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily consists of an investor relations press release announcing the approval of a biosimilar product in Japan. There are no financial statements, detailed financial analysis, or comprehensive report content typical of annual or interim reports. The document is an announcement of a corporate event (product approval) rather than a financial report or management discussion. It is not a call transcript, audit report, or governance information. Given the nature of the content and the form type (6-K), this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories. The document length (8980 characters) is sufficient to contain substantive content but does not contain financial data or report content. Therefore, the classification is RNS with high confidence.
2009-06-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.